Investigational drug · Phase 3
STSA-1002
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "STSA-1002"
First trial start
2023
Dec 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STSA-1002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Respiratory Distress Syndrome (ARDS)
- Acute Respiratory Distress Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "STSA-1002" as an intervention, largest first.
- To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress SyndromePivotal-lookingRecruiting
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT07208591 · 406 participants (planned) · Start Oct 31, 2025 · Primary completion Jul 2026
Drug: STSA-1002 injection; STSA-1002 Injection Placebo · For: Acute Respiratory Distress Syndrome (ARDS)
Sites: Beijing, China; Xiamen, China; Guangzhou, China · 15 sites in all
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05166837 · 52 participants · Start Jan 10, 2022 · Primary completion Jan 12, 2023
Drug: STSA-1002 injection; Placebo and 8 more · For: Healthy
Sites: Hefei, China; Beijing, China; Guangzhou, China · 5 sites in all
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05559125 · 50 participants · Start Nov 8, 2022 · Primary completion Mar 26, 2024
Drug: STSA-1002 Injection; STSA-1005 Injection · For: Healthy Subject
Sites: Xingtai, China
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT06038916 · 47 participants · Start Dec 9, 2023 · Primary completion Mar 20, 2025
Drug: STSA-1002 Injection Placebo; STSA-1002 Injection · For: Acute Respiratory Distress Syndrome
Sites: Bengbu, China; Beijing, China; Chongqing, China · 30 sites in all
- The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy SubjectsCompleted
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05032144 · 40 participants · Start Sep 28, 2021 · Primary completion Mar 31, 2022
Drug: STSA-1002 injection; Placebo and 8 more · For: Healthy
Sites: Overland Park, Kansas
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05497635 · 26 participants · Start Oct 14, 2022 · Primary completion Apr 6, 2023
Drug: STSA-1002 Injection; Placebo · For: Healthy Subject
Sites: Beijing, China; Xingtai, China
- The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy SubjectsCompleted
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05702983 · 20 participants · Start Jan 31, 2023 · Primary completion Apr 11, 2023
Drug: STSA-1002 subcutaneous injection; STSA-1002 subcutaneous injection · For: Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Sites: Overland Park, Kansas
Newest research
PubMed records naming it or its code names, newest first.
- Anti-C5a Antibody STSA-1002 for Patients With ARDS Due to Viral Pneumonia: A Phase 1b/2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial.
Wang Y, Huang X, Cheng Z, et al. · Chest 2026
- Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults.
Fang Y, Wang X, Qi L, et al. · Front Pharmacol 2026
- Preclinical evaluation of STSA-1002, a novel human and rhesus monkeys cross-reactive monoclonal antibody targeting C5a, in acute respiratory distress syndrome models.
Fang Y, Wang X, Xu C, et al. · Int Immunopharmacol 2025
Also in development for Acute Respiratory Distress Syndrome (ARDS)
- CenthaquinePMZ-2010Phase 32 trials
Pharmazz, Inc. · Acute Respiratory Distress Syndrome (ARDS), Hypovolemic Shock
- paridiprubartPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- vilobelimabPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- ALT-100Phase 21 trial
Aqualung Therapeutics Corp. · Acute Respiratory Distress Syndrome (ARDS)
- TISA-818-InjPhase 21 trial
EnliTISA (Shanghai) Pharmaceutical Co., Ltd. · Acute Respiratory Distress Syndrome (ARDS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.